Latest Inhaler Stories
ORLANDO, Fla., Aug. 21, 2012 /PRNewswire/ -- Nephron Pharmaceuticals Corporation (Nephron) is proud to announce Asthmanefrin, a fast acting, safe and effective over-the-counter (OTC) alternative to the discontinued Primatene® Mist chlorofluorocarbon (CFC) inhaler. Asthmanefrin will provide relief for millions of former Primatene® Mist users. The Primatene® Mist CFC inhaler was removed from the market by the Food and Drug Administration (FDA) and the Environmental Protection...
MADISON, Wis., Aug. 6, 2012 /PRNewswire/ -- Asthmapolis announced today that it will be expanding its asthma study at Woodland Healthcare in Woodland, Calif. to also include patients from Mercy Medical Group, another Dignity Health system, located in neighboring Sacramento, Calif. "We're excited to expand the study to include the patients and physicians at Mercy Medical Group," noted David Van Sickle, co-founder and CEO of Asthmapolis. "With the addition of this system, thousands of...
Primatene® Mist Critical For Millions of Asthmatics Lacking Health Insurance; All Manufacturer's Net Profits from Sales of Primatene® Mist will be Donated to Charity WASHINGTON, July 18, 2012 /PRNewswire-USNewswire/ -- The makers of Primatene® Mist have launched a campaign to put the over-the-counter inhaler back on the market in the United States, after it was banned because it contains a small amount of chlorofluorocarbons (CFCs), leaving millions of asthmatics without an...
SEATTLE, July 17, 2012 /PRNewswire/ -- Asthmapolis, a Wisconsin-based company dedicated to advancements in asthma treatment, partnered with Synapse to develop breakthrough technologies for asthma treatment. Combining medication sensors, mobile applications, and analytics, the Asthmapolis sensor attaches to existing rescue inhalers to collect data such as when and where patients experience asthma conditions. Having recently received U.S. Food and Drug Administration clearance,...
MADISON, Wis., July 11, 2012 /PRNewswire-iReach/ -- Asthmapolis announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its asthma sensor system and associated software to healthcare providers and their patients. (Photo: http://photos.prnewswire.com/prnh/20120711/CG38057) "We are thrilled to have achieved this important milestone to support our mission of providing tools to help patients and their healthcare providers better...
OXFORD, England, July 5, 2012 /PRNewswire/ -- Prosonix (Oxford, UK) announced that it has signed a Collaborative Research Agreement with Imperial College London to accelerate the development of engineered Multi-component Particles (MCPs(TM)) as respiratory medicines. The collaboration will see Prosonix working closely with Dr Omar Usmani, an internationally recognised expert in respiratory diseases and inhaled drug delivery at the College's National Heart and Lung...
BEIJING, June 14, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China. The...
This summer, superheroes like Spider-Man, Batman, and even Snow White will showcase their staggering strengths on the big screen. A Rutgers–Camden professor says that children with asthma are the real-life superheroes, facing down breathlessness and operating life-saving devices whenever and wherever asthma attacks strike. Cindy Dell Clark, who teaches anthropology at Rutgers–Camden, recently published research that analyzes Hollywood’s portrayal of children with asthma in the...
SAN FRANCISCO, May 22, 2012 /PRNewswire/ -- Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat(®) Inhaler in adolescents with symptomatic, moderate persistent asthma. The data were presented at the 2012 Annual Meeting of the American Thoracic Society (ATS 2012). Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma(TM) is...
SAN FRANCISCO, May 21, 2012 /PRNewswire/ -- Data from a Phase II trial of olodaterol presented today at the 2012 Annual International Conference of the American Thoracic Society (ATS 2012) compared the efficacy of once-daily (QD) versus twice-daily (BID) olodaterol, a long-acting beta2-agonist (LABA) that Boehringer Ingelheim is evaluating as a possible maintenance treatment for chronic obstructive pulmonary disease (COPD), delivered via the Respimat® Inhaler. In this Phase II...
